Coronavirus (COVID-19): Evidence Collection. Evidence Aid
The COVID-19 pandemic is placing a great strain on healthcare services. Telephone follow up after discharge from hospital might be used to try to reduce post-discharge emergency department visits and hospital readmissions, and to improve outcomes for patients.
In this systematic review, the authors searched for research evaluating the impact of telephone follow-up by people based in primary care on hospital readmissions and emergency department visits after adult patients had been discharged ...
Coronavirus (COVID-19): Evidence Collection. Evidence Aid
Some patients with COVID-19 will develop respiratory failure and need help with their breathing. This might be provided by mechanical ventilation (MV) in an intensive care unit (ICU), but these resources may become limited during a pandemic. Methods might be needed to triage patients to allocate access to these resources and this review examined these for pediatric patients.
In this systematic review, the authors searched for studies evaluating critical care prognosis and multisystem organ ...
Cochrane - Colección Especial - Coronavirus (Covid-19): asistencia en remoto mediante la telesalud
Clinical trials are needed to assess the application of telemedicine to support parents and families of newborns in the NICU, with the length of hospital stay and their perception of care in the NICU as main outcomes.
No survival or clinical efficacy benefit was demonstrated in empirical coverage of atypical pathogens in hospitalized patients with CAP. This conclusion mainly refers to the comparison of quinolone monotherapy versus beta-lactams. More trials should be conducted comparing beta-lactam monotherapy with the same monotherapy combined with a macrolide.
We did not find evidence of the effectiveness using Chinese herbs compared to Western medicines alone.
It is possible that Chinese herbs combined with Western medicines may improve symptoms, quality of life and absorption of pulmonary infiltration, and decrease the corticosteroid dosage for SARS patients.
The evidence is weak because of the poor quality of the included trials. Long‐term follow‐up of these included trials is needed.